BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 17202454)

  • 1. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
    J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
    Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
    J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
    Ooba N; Yamaguchi T; Kubota K
    Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
    Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
    Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
    Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
    J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
    Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Kvernmo T; Härtter S; Burger E
    Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
    Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
    Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline and the risk of valvular lesions in endocrine disease.
    Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
    Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
    De Vecchis R; Esposito C; Ariano C
    Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.